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reduce systemic spread of early stage lung cancer. In vivo experiments 
to explore this are currently being designed and will be presented.
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Adenosine receptors expression in the human lung adenocarcinoma 
cell line (Calu-6)
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An increasing in energy consumption or hypoxia will lead to an en-
hanced production and releasing of adenosine in the tissues or cells. It 
is reasonable to assume, therefore, that metabolically active tumor cells 
may be characterized by a pronounced adenosine release. The local 
release of adenosine may then regulate the growth and development 
of these tumor cells in adenosine receptor-dependent and independent 
ways. Consequently, the presence of deﬁned receptor subtypes will 
be an important determinant for a speciﬁc effect of adenosine on the 
function of a tumor cell. The knowledge of the expression pattern 
of different tumor cells is essential for the development of potential 
therapeutic targets that may aid in more efﬁcient tumor growth control. 
Recently we have identiﬁed the expression proﬁle, signal transduction, 
molecular function and cell growth modulation of adenosine recep-
tor subtypes in the human breast cancer cell lines. To investigate the 
possible roles of adenosine receptors in other types of human cancers, 
in this study, we characterized the expression proﬁle of adenosine 
receptors in the human lung carcinoma cell line (Calu-6). Our purpose 
is to test the hypothesis that diverse human cancer cell lines, accord-
ing to their adenosine receptor subclass status, would show differential 
growth modulation and that this will help tumor growth inhibition. 
RNA was extracted and reverse transcribed to cDNA. PCR primers 
were synthesized from human adenosine receptor cDNA sequences. 
PCR was performed under optimized condition for each receptor 
subtype. Ampliﬁcation of a-actin mRNA served as control for RT-PCR. 
The PCR products were separated on 1.7% agarose gels. Preliminary 
RT-PCR results revealed expression of the adenosine A1, A2A and 
A2B receptors but no expression for A3 subtypes in the human lung 
carcinoma cell line. Further work(s) will be required to understand the 
functional roles of expressed adenosine receptors in the human lung 
cancer cells growth and development.
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We have treated with geﬁtinib for 27 recurrent lung cancer patients who 
underwent surgery at Nagoya City University Hospital. EGFR mutation 
status, copy number and protein expression were evaluated. This study 
included 22 adenocarcinomas and 14 non-smokers.EGFR mutations at 
kinase domain were found from 15 patients. EGFR mutant patients had 
signiﬁcantly better prognosis than patients without EGFR mutations 
(log-rank test, p=0.0039). Non-smoker (p=0.0042) and adenocarcinoma 
patients (p=0.0017) had signiﬁcantly better prognosis. However, gender 
(p=0.0874) and geﬁtinib response (p=0.2779) did not correlated with 
survival. Using the Cox hazard model, EGFR mutation (p=0.0221) 
and smoking status (p=0.0232) were independent prognostic factors. 
FISH analysis were also done for lung cancer tissues at surgery. The 
survival after geﬁtinib therapy was not different between FISH positive 
(4 copy>40% or 15 copy>10%) and FISH negative patients (Log-rank 
test, p=0.1911).EGFR protein expression was evaluated by immunohis-
tochemistry (IHC) using Dako Cytomation EGFR pharmDx Kit.IHC 
results signiﬁcantly correlated with FISH results (p=0.03). However, 
IHC results did not correlated with prognosis after geﬁtinib therapy 
(p=0.9029).
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Background: Synchrotron based Fourier Transform Infrared (FTIR) 
spectroscopy has the potential to become a useful tool to study biologi-
cal systems, in particular cancer [1]. Synchrotron radiation provides ex-
tremely high-ﬂux and bright electromagnetic light at energies ranging 
from the far-infrared to the hard x-ray regions. In the infrared region, 
its intrinsic high brightness allows to measure small areas down to 3 x 
3 µm. Therefore, chemical information regarding the composition and 
distribution of the main components of biological tissues, like proteins, 
lipids, and DNA, can be probed at subcellular level. We have studied 
the application of this technique as a tool helping in the pathological 
diagnosis of lung cancer, and the effects of chemotherapy drugs on lung 
cancer cells assessed at single cell level.
Methods: In vitro growing lung cancer cells where studied using 
synchrotron based FTIR spectroscopy at both at the CCLRC Dares-
bury synchrotron (U. K.) and at the European Synchrotron Radiation 
Facility (Grenoble, France). Lung cancer cells were directly grown on 
aluminium coated slides (lung cancer cells) and incubated overnight in 
the presence or absence of gemcitabine. IR spectra of air-dried or ﬁxed 
samples were obtained in the reﬂectance mode with scanning apertures 
ranging from 5 x 5 µm to 20 x 20 µm at a resolution of 4 cm-1 and co-
adding 256 scans. Parafﬁnised tissue samples from patients with lung 
cancer were placed on Low-e microscope slides (Kevley Technologies, 
USA) and studied in reﬂectance mode.
Results: The addition of gemcitabine to in vitro growing lung cancer 
cells induced changes in their FTIR spectra, at single cell level, in the 
amide I (CO groups) and amide II (NH groups). The peaks correspond-
ing to both areas shifted to lower wavenumbers, indicating cell death. 
The extent of the shifts correlated proportionally to tumour cell sensi-
tivity to gemcitabine. Regarding tumour diagnosis, synchrotron based 
spectroscopy could detect spectral changes between normal cells and 
tumour cells present in the same tissue sample.
